AVAILABLE TO WATCH NOW: AAV-Based Gene Therapy and Prevail Therapeutic's Approach For Neuronopathic Gaucher Diseases & Parkinson's Disease with a GBA Mutation
15 October 2020
The second in a series of educational webinars for our members on the latest developments in gene therapy focused on AAV-based gene therapy and Prevail Therapeutic's approach for neuronopathic Gaucher disease and Parkinson’s disease with a GBA mutation.
Our speakers from Prevail Therapeutics were Dr Eriene Wasef (Medical Director) and Dr Olga Uspenskaya-Cadoz (Vice President, Clinical Development) at Prevail.
WATCH IT NOW
For more details about Prevail's gene therapy please visit: https://www.prevailtherapeutics.com/programs/